Potential clinical applications of vasoactive intestinal peptide: a selected update

Said, 1969, A peptide fraction from lung tissue with prolonged peripheral vasodilator activity, Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum, 107, 51 Said, 1972, Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon, European Journal of Biochemistry, 28, 199, 10.1111/j.1432-1033.1972.tb01903.x Gozes, 1999, Pharmaceutical VIP: prospects and problems, Current Medicinal Chemistry, 6, 1019, 10.2174/092986730611220401163446 Gozes, 2003, VIP and drug design, Current Pharmaceutical Design, 9, 483, 10.2174/1381612033391667 Tourrel, 2002, Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4, Diabetes, 5, 1443, 10.2337/diabetes.51.5.1443 Arimura, 1998, Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems, Japanese Journal of Physiology, 48, 301, 10.2170/jjphysiol.48.301 Tatemoto, 1978, Chemical determination of polypeptide hormones, Proceedings of the National Academy of Sciences of the United States of America, 75, 4115, 10.1073/pnas.75.9.4115 Tatemoto, 1981, Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon-secretin family, Proceedings of the National Academy of Sciences of the United States of America, 78, 6603, 10.1073/pnas.78.11.6603 Yiangou, 1987, Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome, Journal of Clinical Endocrinology and Metabolism, 64, 131, 10.1210/jcem-64-1-131 Bodner, 1985, Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome, Proceedings of the National Academy of Sciences of the United States of America, 82, 3548, 10.1073/pnas.82.11.3548 Laburthe, 2002, VPAC receptors for VIP and PACAP, Receptors Channels, 8, 137, 10.1080/10606820213680 Harmar, 1998, International Union of Pharmacology XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide, Pharmacological Reviews, 50, 265 Harmar, 2001, Family-B G-protein-coupled receptors, Genome Biology, 2, 3013, 10.1186/gb-2001-2-12-reviews3013 Sreedharan, 1993, Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor, Biochemical and Biophysical Research Communications, 193, 546, 10.1006/bbrc.1993.1658 Usdin, 1994, Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions, Endocrinology, 135, 2662, 10.1210/en.135.6.2662 Delgado, 1996, Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes, Journal of Neuroimmunology, 68, 27, 10.1016/0165-5728(96)00063-X Wei, 1996, Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology, Journal of Neuroendocrinology, 8, 811, 10.1046/j.1365-2826.1996.05191.x Harmar, 2004, Distribution of the VPAC2 receptor in peripheral tissues of the mouse, Endocrinology, 145, 1203, 10.1210/en.2003-1058 Voice, 2004, cMaf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide, Journal of Immunology, 172, 7289, 10.4049/jimmunol.172.12.7289 Spengler, 1993, Differential signal transduction by five splice variants of the PACAP receptor, Nature, 365, 170, 10.1038/365170a0 Hashimoto, 1996, Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study, Journal of Comparative Neurology, 371, 567, 10.1002/(SICI)1096-9861(19960805)371:4<567::AID-CNE6>3.0.CO;2-2 Moller, 1996, Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla, Regulatory Peptides, 63, 129, 10.1016/0167-0115(96)00033-X Zeng, 1998, The pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: evidence by immunocytochemistry and RT-PCR, Annals of the New York Academy of Sciences, 865, 147, 10.1111/j.1749-6632.1998.tb11173.x Miampamba, 2002, Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons, Regulatory Peptides, 105, 145, 10.1016/S0167-0115(02)00003-4 McCulloch, 2002, Additional signals from VPAC/PAC family receptors, Biochemical Society Transactions, 30, 441, 10.1042/bst0300441 Quik, 1978, Effect of vasoactive intestinal peptide (VIP) and other peptides on cAMP accumulation in rat brain, Biochemical Pharmacology, 27, 2209, 10.1016/0006-2952(78)90079-5 Yajima, 1998, VIP induces the translocation and degradation of the alpha subunit of Gs protein in rat pituitary GH4C1 cells, Journal of Biochemistry (Tokyo), 123, 1024, 10.1093/oxfordjournals.jbchem.a022038 Paul, 1989, Decreased selectivity of vasoactive intestinal peptide receptors by GTP, Biochemical Pharmacology, 38, 699, 10.1016/0006-2952(89)90220-7 Lelievre, 1998, Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase, Journal of Biological Chemistry, 273, 19685, 10.1074/jbc.273.31.19685 McCulloch, 2001, ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant, Molecular Pharmacology, 59, 1523, 10.1124/mol.59.6.1523 Murthy, 1998, Differential regulation of phospholipase A2 (PLA2)-dependent Ca2+ signaling in smooth muscle by cAMP- and cGMP-dependent protein kinases. Inhibitory phosphorylation of PLA2 by cyclic nucleotide-dependent protein kinases, Journal of Biological Chemistry, 273, 34519, 10.1074/jbc.273.51.34519 Koch, 1991, Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea, Gastroenterology, 100, 99, 10.1016/0016-5085(91)90588-C Hejna, 2001, Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract, Anticancer Research, 21, 1183 Umemoto, 2003, Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis, Journal of Dermatological Science, 31, 161, 10.1016/S0923-1811(03)00004-5 Petkov, 2003, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, Journal of Clinical Investigation, 111, 1339, 10.1172/JCI17500 Wang, 2003, Gastrointestinal dysmotility in patients with acute pancreatitis, Journal of Gastroenterology and Hepatology, 18, 57, 10.1046/j.1440-1746.2003.02898.x Calhoun, 2003, Serum peptide profiles in patients with carcinoid tumors, American Journal of Surgery, 186, 28, 10.1016/S0002-9610(03)00115-6 Kassim, 2002, Serum nitrates and vasoactive intestinal peptide in patients with gastroesophageal reflux disease, Clinical Biochemistry, 35, 641, 10.1016/S0009-9120(02)00399-5 O'Dorisio, 2002, Age-dependent levels of plasma neuropeptides in normal children, Regulatory Peptides, 109, 189, 10.1016/S0167-0115(02)00203-3 Chongsrisawat, 2003, Relationship between vasoactive intestinal peptide and intrapulmonary vascular dilatation in children with various liver diseases, Acta Paediatrica, 92, 1411, 10.1111/j.1651-2227.2003.tb00824.x Gozes, 1994, Neuropeptide-regulation of mitosis, Annals of the New York Academy of Sciences, 739, 253, 10.1111/j.1749-6632.1994.tb19827.x Reubi, 2000, Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin, Cancer Research, 60, 3105 Madsen, 2001, Estradiol down regulates expression of vasoactive intestinal polypeptide receptor type-1 in breast cancer cell lines, Molecular and Cellular Endocrinology, 172, 203, 10.1016/S0303-7207(00)00341-5 Bloom, 1973, Vasoactive intestinal peptide and watery-diarrhea syndrome, Lancet, 2, 14, 10.1016/S0140-6736(73)91947-8 Park, 1996, Vasoactive intestinal polypeptide-secreting tumours: biology and therapy, Baillieres Clinical Gastroenterology, 10, 673, 10.1016/S0950-3528(96)90018-4 Gozes, 1992, The VIP gene is expressed in non-small cell lung cancer cell lines, Biomedical Research, 13, 37 Moody, 2003, VIP as a trophic factor in the CNS and cancer cells, Peptides, 24, 163, 10.1016/S0196-9781(02)00290-5 Lilling, 1995, Inhibition of human neuroblastoma growth by a specific VIP antagonist, Journal of Molecular Neuroscience, 5, 231, 10.1007/BF02736724 Fruhwald, 1998, Neuropeptides in developmental tumors of the central and peripheral nervous system, Annals of the New York Academy of Sciences, 865, 420, 10.1111/j.1749-6632.1998.tb11208.x Wollman, 1993, Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells, Brain Research, 624, 339, 10.1016/0006-8993(93)90100-2 Sharma, 2001, Vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells, Journal of Molecular Neuroscience, 17, 331, 10.1385/JMN:17:3:331 Levy, 2002, In vitro and in vivo treatment of colon cancer by VIP antagonists, Regulatory Peptides, 109, 127, 10.1016/S0167-0115(02)00195-7 Moody, 2004, VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice, Life Sciences, 74, 1345, 10.1016/j.lfs.2003.07.043 Gozes, 1995, A VIP hybrid antagonist: from developmental neurobiology to clinical applications, Cellular and Molecular Neurobiology, 15, 675, 10.1007/BF02071131 Moody, 2002, (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist, Journal of Molecular Neuroscience, 18, 29, 10.1385/JMN:18:1-2:29 Gozes, 1995, Superactive lipophilic peptides discriminate multiple VIP receptors, Journal of Pharmacology and Experimental Therapeutics, 273, 161 Moody, 2000, VPAC1 receptors and lung cancer, Annals of the New York Academy of Sciences, 921, 26, 10.1111/j.1749-6632.2000.tb06947.x Gelber, 2001, Lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines, Cancer, 92, 2172, 10.1002/1097-0142(20011015)92:8<2172::AID-CNCR1560>3.0.CO;2-4 Zia, 2000, (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines, Life Sciences, 66, 379, 10.1016/S0024-3205(99)00604-9 Moody, 2001, VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells, Breast Cancer Research and Treatment, 68, 55, 10.1023/A:1017994722130 Plonowski, 2002, Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity, International Journal of Cancer, 98, 624, 10.1002/ijc.10221 Moody, 2002, VIP-ellipticine derivatives inhibit the growth of breast cancer cells, Life Sciences, 71, 1005, 10.1016/S0024-3205(02)01741-1 Maruno, 1993, Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody, Life Sciences, 52, PL267, 10.1016/0024-3205(93)90640-O Reubi, 2003, Peptide receptors as molecular targets for cancer diagnosis and therapy, Endocrine Reviews, 24, 389, 10.1210/er.2002-0007 Riccabona, 2003, Peptide targeted imaging of cancer, Cancer Biotherapy and Radiopharmaceuticals, 18, 675, 10.1089/108497803770418238 Hollander, 2003, Inflammatory bowel diseases and brain-gut axis, Journal of Physiology and Pharmacology, 54, 183 Voice, 2003, Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice, Journal of Immunology, 170, 308, 10.4049/jimmunol.170.1.308 Abad, 2003, Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease, Gastroenterology, 124, 961, 10.1053/gast.2003.50141 Joo, 2002, Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands, Journal of Biological Chemistry, 277, 50710, 10.1074/jbc.M208826200 Delgado, 2000, Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock, European Journal of Immunology, 30, 3236, 10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L Delgado, 2001, Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease, Nature Medicine, 7, 563, 10.1038/87887 Foey, 2003, Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis, Arthritis Research and Therapy, 5, R317, 10.1186/ar999 Gozes, 1987, Developmental expression of the VIP-gene in brain and intestine, Brain Research, 388, 137, 10.1016/0169-328X(87)90007-6 Brenneman, 1986, Vasoactive intestinal peptide and electrical activity influence neuronal survival, Proceedings of the National Academy of Sciences of the United States of America, 83, 1159, 10.1073/pnas.83.4.1159 Gozes, 1996, Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide, Proceedings of the National Academy of Sciences of the United States of America, 93, 427, 10.1073/pnas.93.1.427 Gozes, 1999, Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design, Proceedings of the National Academy of Sciences of the United States of America, 96, 4143, 10.1073/pnas.96.7.4143 Glowa, 1992, Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist, Brain Research, 570, 49, 10.1016/0006-8993(92)90562-N Gozes, 1993, Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene, Journal of Molecular Neuroscience, 4, 185, 10.1007/BF02782501 Brenneman, 1996, A femtomolar-acting neuroprotective peptide, Journal of Clinical Investigation, 97, 2299, 10.1172/JCI118672 Bassan, 1999, Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide, Journal of Neurochemistry, 72, 1283, 10.1046/j.1471-4159.1999.0721283.x Gozes, 2000, A novel VIP responsive gene. Activity dependent neuroprotective protein, Annals of the New York Academy of Sciences, 921, 115, 10.1111/j.1749-6632.2000.tb06957.x Gozes, 2003, From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division, Journal of Molecular Neuroscience, 20, 315, 10.1385/JMN:20:3:315 Divinski, 2004, A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication, Journal of Biological Chemistry, 279, 28531, 10.1074/jbc.M403197200 Blondel, 2000, A glia-derived signal regulating neuronal differentiation, Journal of Neuroscience, 20, 8012, 10.1523/JNEUROSCI.20-21-08012.2000 Brenneman, 2003, Complex array of cytokines released by vasoactive intestinal peptide, Neuropeptides, 37, 111, 10.1016/S0143-4179(03)00022-2 Delgado, 2003, Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma, Federation of American Societies for Experimental Biology Journal, 17, 1922, 10.1096/fj.02-1029fje Offen, 2000, Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease, Brain Research, 854, 257, 10.1016/S0006-8993(99)02375-6 Eilam, 1999, Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus, Hippocampus, 9, 534, 10.1002/(SICI)1098-1063(1999)9:5<534::AID-HIPO7>3.0.CO;2-R Gressens, 1999, Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives, Journal of Pharmacology and Experimental Therapeutics, 288, 1207 Gressens, 1993, Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos, Nature, 362, 155, 10.1038/362155a0 Gressens, 1994, Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse, Journal of Clinical Investigation, 94, 2020, 10.1172/JCI117555 Servoss, 2001, IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth, Endocrinology, 142, 3348, 10.1210/en.142.8.3348 Pinhasov, 2003, Activity-dependent neuroprotective protein: a novel gene essential for brain formation, Brain Research. Developmental Brain Research, 144, 83, 10.1016/S0165-3806(03)00162-7 Nelson, 2001, Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation, Annals of Neurology, 49, 597, 10.1002/ana.1024 Adeghate, 2001, Diabetes mellitus is associated with a decrease in vasoactive intestinal polypeptide content of gastrointestinal tract of rat, Archives of Physiology and Biochemistry, 109, 246, 10.1076/apab.109.3.246.11587 Tsutsumi, 2002, A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes, Diabetes, 51, 1453, 10.2337/diabetes.51.5.1453 Asnicar, 2002, Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate, Endocrinology, 143, 3994, 10.1210/en.2002-220354 Avidor, 1989, VIP-mRNA is increased in hypertensive rats, Brain Research, 503, 304, 10.1016/0006-8993(89)91679-X Henning, 2001, Vasoactive intestinal peptide: cardiovascular effects, Cardiovascular Research, 49, 27, 10.1016/S0008-6363(00)00229-7 Saetrum Opgaard, 2001, Vasoactive intestinal peptide has a direct positive inotropic effect on isolated human myocardial trabeculae, Clinical Science (London), 101, 637, 10.1042/CS20010076 Gunaydin, 2002, The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine, Cardiovascular Surgery, 10, 138, 10.1016/S0967-2109(01)00126-0 Lucia, 2003, Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure?, Clinical Endocrinology (Oxford), 59, 723, 10.1046/j.1365-2265.2003.01913.x Ye, 2004, Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension, European Journal of Pharmacology, 485, 235, 10.1016/j.ejphar.2003.11.069 Bornstein, 1996, Cellular communication in the neuro-adrenocortical axis: role of vasoactive intestinal polypeptide (VIP), Endocrine Research, 22, 819, 10.1080/07435809609043781 Cobb, 1997, Direct stimulation of cortisol secretion from the human NCI H295 adrenocortical cell line by vasoactive intestinal polypeptide, Journal of Hypertension, 15, 1735, 10.1097/00004872-199715120-00081 Haidan, 1998, Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP), Peptides, 19, 1511, 10.1016/S0196-9781(98)00115-6 Nicol, 2004, Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors, Journal of Molecular Endocrinology, 32, 869, 10.1677/jme.0.0320869 Fang, 2001, The stimulatory effect of vasoactive intestinal peptides on the cortisol production of guinea pig zona fasciculata cells: an extra-ACTH regulatory model of the adrenocortical function, Chinese Journal of Physiology, 44, 73 Mazzocchi, 2002, Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland, Journal of Clinical Endocrinology and Metabolism, 87, 2575, 10.1210/jc.87.6.2575 Watanobe, 1997, A suppressive effect of dexamethasone (DEX) on adrenocorticotropin (ACTH) response to vasoactive intestinal peptide (VIP) in Cushing's disease: a parallel modulation by DEX of ACTH responses to VIP and corticotropin-releasing hormone, Neuropeptides, 31, 35, 10.1016/S0143-4179(97)90017-2 Balsa, 1998, Direct action of serotonin on prolactin, growth hormone, corticotropin and luteinizing hormone release in cocultures of anterior and posterior pituitary lobes: autocrine and/or paracrine action of vasoactive intestinal peptide, Neuroendocrinology, 68, 326, 10.1159/000054381 Egli, 2004, Rhythmic secretion of prolactin in rats: action of oxytocin coordinated by vasoactive intestinal polypeptide of suprachiasmatic nucleus origin, Endocrinology, 145, 3386, 10.1210/en.2003-1710 Tohei, 2000, Hypothyroidism increases prolactin secretion and decreases the intromission threshold for induction of pseudopregnancy in adult female rats, Physiology and Behavior, 69, 391, 10.1016/S0031-9384(00)00224-9 Tohei, 2004, Studies on the functional relationship between thyroid, adrenal and gonadal hormones, Journal of Reproduction and Development, 50, 9, 10.1262/jrd.50.9 Rostene, 1997, Steroid regulation of vasoactive intestinal peptide (VIP), Stress, 2, 79, 10.3109/10253899709014739 Chew, 1997, Transcription of the vasoactive intestinal peptide gene in response to glucocorticoids: differential regulation of alternative transcripts is modulated by a labile protein in rat anterior pituitary, Molecular and Cellular Endocrinology, 130, 83, 10.1016/S0303-7207(97)00076-2 Gozes, 1989, Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus, Journal of Molecular Neuroscience, 1, 55, 10.1007/BF02918891 Granoth, 2000, VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes, FEBS Letters, 475, 78, 10.1016/S0014-5793(00)01628-8 Granoth, 2000, VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model, FEBS Letters, 475, 71, 10.1016/S0014-5793(00)01629-X Gozes, 1994, Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment, Endocrinology, 134, 2121, 10.1210/en.134.5.2121 Gozes, 1992, A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model, Journal of Clinical Investigation, 90, 810, 10.1172/JCI115955 Ashur-Fabian, 1997, Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides, Journal of Molecular Neuroscience, 9, 211, 10.1007/BF02800503 Ashur-Fabian, 1999, SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival, Peptides, 20, 629, 10.1016/S0196-9781(99)00017-0